checkAd

    Sellas Life Sciences Group (ehemals Galena Biopharma) (Seite 233)

    eröffnet am 30.10.12 22:43:19 von
    neuester Beitrag 19.01.24 22:21:17 von
    Beiträge: 2.935
    ID: 1.177.530
    Aufrufe heute: 0
    Gesamt: 345.688
    Aktive User: 0

    ISIN: US81642T2096 · WKN: A2PU3T · Symbol: RXK3
    0,9320
     
    EUR
    -2,51 %
    -0,0240 EUR
    Letzter Kurs 28.03.24 Tradegate

    Werte aus der Branche Pharmaindustrie

    WertpapierKursPerf. %
    4,2800+56,20
    0,7500+50,00
    0,7630+26,53
    0,5151+25,28
    15,160+19,94
    WertpapierKursPerf. %
    5,0101-15,80
    3,8500-16,12
    7,5000-16,67
    1,8500-20,94
    3,6400-38,62

    Beitrag zu dieser Diskussion schreiben

     Durchsuchen
    • 1
    • 233
    • 294

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 05.09.14 20:42:04
      Beitrag Nr. 615 ()
      Heute Essplosione !!

      Kommt Roche doch noch ??
      Avatar
      schrieb am 03.09.14 21:00:13
      Beitrag Nr. 614 ()
      Galena announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the New York Palace Hotel in New York, NY. on Tuesday, September 9, 2014 at 2:55 p.m.
      :cool:
      Avatar
      schrieb am 27.08.14 19:44:38
      Beitrag Nr. 613 ()
      analyst Vernon T. Bernardino reiterated a Buy rating on Galena Biopharma
      Avatar
      schrieb am 26.08.14 20:58:20
      Beitrag Nr. 612 ()
      Avatar
      schrieb am 26.08.14 19:30:41
      Beitrag Nr. 611 ()
      Antwort auf Beitrag Nr.: 47.614.290 von lunatics am 26.08.14 18:01:55
      Zitat von lunatics: Aktie zischt ab. Insider kaufen wieder. :D


      Denke eher hat nen Technischen Hintergrund, von über USD 3.00 auf USD 2.10 war doch etwas heftig...

      Trading Spotlight

      Anzeige
      Nurexone Biologic
      0,5400EUR +11,11 %
      Technisches (täglich, wöchentlich, monatlich) & Analysten “Strong Buy”-Rating!mehr zur Aktie »
      Avatar
      schrieb am 26.08.14 18:01:55
      Beitrag Nr. 610 ()
      Aktie zischt ab. Insider kaufen wieder. :D
      1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
      Avatar
      schrieb am 21.08.14 19:53:27
      Beitrag Nr. 609 ()
      Wann ist die nächste Kapitalerhöhung? Zu vielleicht $1.50 bin ich auch mal wieder für eine kurze Erholungsphase mit dabei.
      Avatar
      schrieb am 21.08.14 13:08:03
      Beitrag Nr. 608 ()
      Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer

      PORTLAND, Ore., Aug. 21, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., has been appointed as President and Chief Executive Officer, effective immediately. Dr. Schwartz was previously Galena's Executive Vice President and Chief Operating Officer. He replaces Mark J. Ahn, Ph.D. who has resigned as the President and CEO and as a director of the company to pursue other long held personal and professional goals. It is expected that Dr. Schwartz will also be appointed to Galena's Board of Directors.

      "Dr. Schwartz brings more than 30 years of experience in the biotechnology and life science industry, and on behalf of the Board of Directors, I am pleased to announce his appointment as President and CEO of Galena," said Sanford J. Hillsberg, Chairman of the Board of Directors of Galena. "As the former CEO of Apthera when it was purchased by Galena, Mark has been involved with our lead development asset, NeuVax, since 2010. During his time at Galena, Mark has worked across all of the company's programs and has also managed intellectual property efforts, acquisitions, and partnerships. He also oversaw the initiation of our commercialization efforts. We believe Mark's experience, commitment, integrity and focus will provide excellent leadership for the company."

      Mr. Hillsberg added, "We are grateful for Mark Ahn's seven years of service with Galena as a member of the Board of Directors, and as President and CEO for the past three years. Mark's leadership moved Galena from a pre-clinical company to a fully integrated, revenue generating organization with a broad and diverse pipeline, establishing the base from which we can continue to grow."

      "I am grateful to the Board of Directors for this opportunity and am excited to lead our talented and dedicated team. Galena's corporate strategy, with two commercial products and multiple promising and innovative development programs, provides a solid basis for long-term value. I am passionate about our prospects, and look forward to working for the benefit of patients, physicians, and shareholders," said Dr. Schwartz.

      Dr. Schwartz brings more than 30 years of experience in the biotechnology and life science industry and was appointed Executive Vice President and Chief Operating Officer in 2011 following Galena's acquisition of Apthera, Inc. where he served as the company's President and Chief Executive Officer. Prior to Apthera, Dr. Schwartz served for five years as President and CEO of Bayhill Therapeutics, a company developing an innovative DNA vaccine platform for the treatment of autoimmune diseases where he completed a successful partnership with Genentech for the development of the company's Type 1 diabetes vaccine. He had also served as President and CEO of Calyx Therapeutics, which expanded significantly, and completed key Phase 1 and Phase 2 international clinical trials of novel anti-inflammatory compounds during his tenure. Earlier in his career, Dr. Schwartz held a range of positions in R&D, marketing, sales, business development and executive management at Trega BioSciences, Incyte Genomics, Synteni, Tripos Inc., Applied Biosystems and DuPont Diagnostics.

      Dr. Schwartz is currently on the advisory board for BayBio, a Director of Targazyme Pharmaceuticals, and is on the faculty of San Jose State University in the Masters of Biotechnology Program. He is also a former Board member of the Biotechnology Industry Association. Dr. Schwartz received his Bachelor of Arts in Chemistry from Grinnell College and his Ph.D. in Chemistry from Arizona State University.
      Avatar
      schrieb am 21.08.14 09:25:43
      Beitrag Nr. 607 ()
      Zitat von bierteufel:
      Zitat von lunatics: ...

      Ich nicht.


      er auch nicht...

      http://www.oregonlive.com/health/index.ssf/2014/08/galena_bi…


      Berechtigt aber vermutlich nicht Kursförderlich..
      Avatar
      schrieb am 21.08.14 08:49:59
      Beitrag Nr. 606 ()
      Zitat von lunatics:
      Zitat von Aurum2010: Zudem hat sich Abstral Umsatztechnisch nicht wie erwartet entwickelt... Ich bleibe dennoch dabei.


      Ich nicht.


      er auch nicht...

      http://www.oregonlive.com/health/index.ssf/2014/08/galena_bi…
      • 1
      • 233
      • 294
       DurchsuchenBeitrag schreiben


      Investoren beobachten auch:

      WertpapierPerf. %
      0,00
      -1,30
      +0,60
      +1,65
      +0,17
      +2,09
      +1,60
      -17,51
      +0,62
      +914,57
      Sellas Life Sciences Group (ehemals Galena Biopharma)